Compare ASTRAZENECA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AUROBINDO PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AUROBINDO PHARMA ASTRAZENECA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 115.9 17.1 676.3% View Chart
P/BV x 35.5 3.7 956.7% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
AUROBINDO PHARMA
Mar-19
ASTRAZENECA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278830 154.0%   
Low Rs883527 167.4%   
Sales per share (Unadj.) Rs228.4333.9 68.4%  
Earnings per share (Unadj.) Rs10.440.4 25.7%  
Cash flow per share (Unadj.) Rs16.351.8 31.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.8237.1 41.7%  
Shares outstanding (eoy) m25.00585.91 4.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.0 232.7%   
Avg P/E ratio x104.216.8 619.9%  
P/CF ratio (eoy) x66.413.1 506.8%  
Price / Book Value ratio x10.92.9 382.1%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m27,008397,569 6.8%   
No. of employees `0001.417.9 7.6%   
Total wages/salary Rs m1,53525,849 5.9%   
Avg. sales/employee Rs Th4,210.910,956.9 38.4%   
Avg. wages/employee Rs Th1,132.21,447.7 78.2%   
Avg. net profit/employee Rs Th191.11,324.3 14.4%   
INCOME DATA
Net Sales Rs m5,710195,636 2.9%  
Other income Rs m1231,553 7.9%   
Total revenues Rs m5,833197,189 3.0%   
Gross profit Rs m46339,519 1.2%  
Depreciation Rs m1476,680 2.2%   
Interest Rs m02,626 0.0%   
Profit before tax Rs m43831,767 1.4%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1797,269 2.5%   
Profit after tax Rs m25923,645 1.1%  
Gross profit margin %8.120.2 40.1%  
Effective tax rate %40.822.9 178.5%   
Net profit margin %4.512.1 37.5%  
BALANCE SHEET DATA
Current assets Rs m3,209153,645 2.1%   
Current liabilities Rs m2,070120,429 1.7%   
Net working cap to sales %20.017.0 117.6%  
Current ratio x1.61.3 121.5%  
Inventory Days Days72135 53.5%  
Debtors Days Days3564 54.8%  
Net fixed assets Rs m790103,909 0.8%   
Share capital Rs m50586 8.5%   
"Free" reserves Rs m2,419138,322 1.7%   
Net worth Rs m2,469138,908 1.8%   
Long term debt Rs m01,800 0.0%   
Total assets Rs m4,605264,544 1.7%  
Interest coverage xNM13.1-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.7 167.7%   
Return on assets %5.69.9 56.7%  
Return on equity %10.517.0 61.6%  
Return on capital %17.723.8 74.4%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m30097,316 0.3%   
Fx outflow Rs m2,01540,589 5.0%   
Net fx Rs m-1,71556,727 -3.0%   
CASH FLOW
From Operations Rs m8816,220 0.5%  
From Investments Rs m-94-28,768 0.3%  
From Financial Activity Rs mNA19,191 0.0%  
Net Cashflow Rs m-66,656 -0.1%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 15.7 27.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   12,856 69,601 18.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  TORRENT PHARMA  DISHMAN PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Higher; JSW Steel & Tata Steel Top Gainers(09:30 am)

Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Mar 3, 2021 11:44 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS